BioSpace News Archive

EmbarkNeuro today announced that the first patient has been dosed in its Phase 2 trial of ANC-501, a first-in-class vasopressin 1b (V1b) receptor antagonist for the treatment of major depressive disorder (MDD).

BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy and the broader biopharma markets, provided an update on the expansion of its intellectual property estate.

Graphite Bio, Inc. today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET.

Healiva ®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE.

Thermo Fisher Scientific Inc. will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST).

Cardio D iagnostics Holdings Inc (Nasdaq: CDIO) today announced it would be presenting at the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st , 2022, at the New York Athletic Club in New York City.

Cryos International Sperm and Egg Bank today announced a published scientific study which suggests that the use of Virtual Reality (VR) headsets during sperm donation has a positive effect on sperm quality.

Vektor Medical , developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced it presented new data on its vMap ® technology that demonstrated potential utility in patients with adult congenital heart disease (ACHD).

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress for Hair Research.

Castle Biosciences, Inc. today announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh.